Total number of people with adverse events, · people with acute ischemic stroke
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in total number of people with adverse events, compared with placebo (low certainty).
1 finding from 1 review
Death or dependence · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
Early death (within 2 weeks of stroke onset) · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life · people with acute ischemic stroke
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Recurrence of stroke · people with stroke or transient ischaemic attack
The intervention probably leads to lower recurrence of stroke (moderate certainty).
1 finding from 1 review
Intervention not reported
Reported adverse events · people with stroke or transient ischaemic attack
The intervention showed no clear difference in reported adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Serious vascular events · people with stroke or transient ischaemic attack
The intervention may leads to lower serious vascular events (low certainty).
1 finding from 1 review
Intervention not reported
Deaths due to vascular events · people with stroke or transient ischaemic attack
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Disability due to vascular events · people with stroke or transient ischaemic attack
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Improvement in quality of life · people with stroke or transient ischaemic attack
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Insulin sensitivity · people with stroke or transient ischaemic attack
1 finding from 1 review
MACE ‐ not reported · survivors of stroke due to intracerebral haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional ability · survivors of stroke due to intracerebral haemorrhage with atrial fibrillation
Summary of findings table ‐ Starting long‐term therapeutic dose oral… showed no clear difference in functional status (mRS 0‐2) compared with avoiding anticoagulation (low certainty).
1 finding from 1 review
MACE · survivors of stroke due to intracerebral haemorrhage
Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in MACE compared with avoiding antithrombotic therapy (moderate certainty).
1 finding from 1 review
Death · survivors of stroke due to intracerebral haemorrhage
Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in death compared with avoiding antithrombotic therapy (moderate certainty).
1 finding from 1 review
All major occlusive vascular events · survivors of stroke due to intracerebral haemorrhage
Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in all major occlusive vascular events compared with avoiding antithrombotic therapy (moderate certainty).
1 finding from 1 review
Intracerebral haemorrhage (ICH) · survivors of stroke due to intracerebral haemorrhage
Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in intracerebral haemorrhage (ICH) compared with avoiding antithrombotic therapy (moderate certainty).
1 finding from 1 review
Functional outcomes · survivors of stroke due to intracerebral haemorrhage
Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in fnctional status (mRS 0‐2) compared with avoiding antithrombotic therapy (moderate certainty).
1 finding from 1 review
MACE · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral…
Summary of findings table ‐ Cilostazol showed no clear difference in MACE compared with aspirin (low certainty).
1 finding from 1 review
Death · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of prior intracerebral…
Summary of findings table ‐ Cilostazol showed no clear difference in death compared with aspirin (low certainty).
1 finding from 1 review